ArticleACS omega2026
Analytical and Clinical Validation of a Remote Laboratory Test for Prothrombin Time and INR Determination in Patients with Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with antiphospholipid antibodies, leading to coagulation imbalance, thrombosis, and obstetric complications. It may occur as a primary condition or in association with systemic lupus erythematosus (SLE). Patients with APS often require long-term anticoagulation therapy, monitored by prothrombin time (PT) expressed as international normalized ratio (INR). Remote laboratory testing (RLT) devices may improve monitoring by providing faster and more convenient results; however, their accuracy in APS patients remains uncertain. This study aimed to validate a rapid and portable device (bSens.INR) for PT/INR measurement in patients with APS and SLE receiving warfarin, compared to a control group without these conditions. Accuracy, repeatability, and agreement with the standard laboratory method were evaluated according to established guidelines. A total of 40 PT/INR measurements were obtained using the bSens.INR and 20 using the standard method. Overall concordance was 77.5%, with lower agreement in APS/SLE patients (60%) compared to controls (95%). Approved results showed 100% repeatability. A strong positive correlation was observed between methods (Spearman
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.